Company profile for Werewolf Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Werewolf Therapeutics is backed by leading life science investors and led by an experienced team with a proven track record of developing novel medicines for the treatment of cancer. INDUKINE™ molecules are systemically administered in an inactive form and, upon entering the tumor microenvironment, are selectively activated to deliver the full biological potency of cytokines and recruit a powerful anti-tumor immune response....
Werewolf Therapeutics is backed by leading life science investors and led by an experienced team with a proven track record of developing novel medicines for the treatment of cancer. INDUKINE™ molecules are systemically administered in an inactive form and, upon entering the tumor microenvironment, are selectively activated to deliver the full biological potency of cytokines and recruit a powerful anti-tumor immune response. Therefore, INDUKINE™ molecules deliver maximum therapeutic potential while minimizing unwanted off-target effects in non-tumor tissues.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1030 Massachusetts Avenue Suite 210 Cambridge, MA 02138
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/07/3183699/0/en/Werewolf-Therapeutics-Presents-Data-Expanding-Its-PREDATOR-Platform-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-40th-Annual-Meeting.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/08/3163279/0/en/Werewolf-Therapeutics-Receives-Fast-Track-Designation-from-the-U-S-FDA-for-WTX-124-an-Investigational-Therapy-for-the-Treatment-of-Cancer.html

GLOBENEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2025/10/03/3160964/0/en/Werewolf-Therapeutics-to-Present-Posters-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-40th-Annual-Meeting.html

GLOBENEWSWIRE
03 Oct 2025

https://www.globenewswire.com/news-release/2025/09/02/3142602/0/en/Werewolf-Therapeutics-to-Participate-in-the-Upcoming-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

GLOBENEWSWIRE
02 Sep 2025

https://www.globenewswire.com/news-release/2025/08/14/3133300/0/en/Werewolf-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
14 Aug 2025

https://www.globenewswire.com/news-release/2025/07/09/3112488/0/en/Werewolf-Therapeutics-to-Participate-in-the-KidneyCAN-7th-Annual-Kidney-Cancer-Research-Summit.html

GLOBENEWSWIRE
09 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty